Neutral Dr Reddys Laboratories; target of Rs 1180: Motilal Oswal

Moneycontrol • 6 days ago

Original source

Key Investment Pillars

  • Niche product launches, such as g-Bosutinib in North America, are driving earnings growth.
  • Domestic formulation segment is showing robust growth momentum due to new brand launches, price hikes, and higher volumes.
  • Emerging markets sales are growing, driven by strong momentum in Russia and the Rest of the World.
  • The company is working on reviving Semaglutide off-take and getting timely regulatory approval for abatacept.

Thesis Validation Checklist

  • Watch for steady launch momentum in niche products and growth in the domestic formulation segment.
  • Monitor the company's ability to revive Semaglutide off-take and receive regulatory approval for abatacept.
  • Track the company's progress in expanding its presence in emerging markets and improving its profitability.